{
  "first_published_at": "2012-05-22", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON152723", 
  "title": "Fingolimod (Gilenya▼): not recommended for patients at known risk of cardiovascular adverse events. New advice for extended early monitoring for those with significant bradycardia or heart block after the first dose. ", 
  "tags": "{\"parsed_therapeutic\": [\"immunosuppression-transplantation\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Immunosuppression and transplantation\"]}", 
  "_document_number": 114, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "immunosuppression-transplantation"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Fingolimod (Gilenya&#9660;): not recommended for patients at known risk of cardiovascular adverse events. New advice for extended early monitoring for those with significant bradycardia or heart block after the first dose. </h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: May 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Fingolimod is known to cause transient bradycardias and heart block after the first dose. Fingolimod is now not recommended in patient groups at high risk of cardiovascular adverse events, such as those with significant QT prolongation or history of bradycardia, ischaemic heart disease, cardiac failure, cerebrovascular disease, uncontrolled hypertension, and those receiving antiarrhythmic or heart-rate lowering drugs.<br>\n<br>\nMonitoring advice after the first dose has been updated. All patients should be monitored before, during, and immediately after the first 6 hours of treatment. If the patient&#8217;s heart rate decreases to its lowest point at the end of the 6-hour treatment period, monitoring should be extended until heart rate increases. Monitoring should also be extended at least overnight if significant atrioventricular block, bradycardia, or QTc prolongation occurs (see below)<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Fingolimod (Gilenya) is authorised to treat relapsing-remitting multiple sclerosis in patients whose disease has failed to respond to beta-interferon or is severe and getting worse rapidly. Fingolimod is a sphingosine -1 phosphate receptor ligand.</p>\n\n<p>We first highlighted changes to the monitoring advice for fingolimod in <a href=\"http://http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON143608\" target=\"_blank\">February 2012.</a></p>\n\n<p>We now provide updated advice to avoid use in high risk groups and extend monitoring in some patients. The latest advice follows further review of world-wide data including 15 cases of sudden or unexplained death with fingolimod. Most of the deaths and cardiovascular events had occurred in patients with either a history of cardiovascular problems, such as atrioventricular block or bradycardia, or those who were also taking other medicines. However the data reviewed were not conclusive as to whether Gilenya was the cause of the deaths.</p>\n\n<p>The maximum effect of fingolimod on decreasing the heart rate occurred within six hours after the first dose in most patients; this decrease in heart rate can be reversed if necessary by giving atropine or isoprenaline (see statement from the <a href=\"http://http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdf\" target=\"_blank\">European Medicines Agency</a>).</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Updated advice:</strong></p>\n\n<p><span style=\" text-decoration: underline;\"><strong>Fingolimod is now not recommended in the following high-risk patients:-</strong></span></p>\n\n<p>a) <strong>Those with the following medical conditions:</strong></p>\n\n<ul>\n<li>2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block</li>\n\n<li>Significant QT prolongation (QTc &#62;470 ms in women, or &#62;450 ms in men)</li>\n\n<li>History of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnea.<br />\n</li>\n</ul>\n\n<p>b) <strong>Those receiving the following antiarrhythmic or heart-rate-lowering drugs:</strong></p>\n\n<ul>\n<li>Class Ia antiarrhythmics (eg, quinidine, disopyramide) or class III antiarrhythmics (eg, amiodarone, sotalol)</li>\n\n<li>Beta blockers</li>\n\n<li>Heart rate-lowering calcium channel blockers (eg, verapamil, diltiazem or ivabradine)</li>\n\n<li>Other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic agents or pilocarpine).</li>\n</ul>\n\n<p>In such patients, treatment with Gilenya should be considered only if the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought prior to initiation of Gilenya treatment. This advice should include, if appropriate, the possibility to switch any concomitant medicine to treatments that are not antiarrhythmic and do not lower the heart rate. If treatment with Gilenya for these patients is considered, monitoring at least overnight following the first dose should be initiated.</p>\n\n<p><strong><span style=\" text-decoration: underline;\">Updated monitoring advice: For all patients receiving fingolimod, monitoring before, during and after the first dose should include:</span></strong></p>\n\n<p><strong>Pre-treatment:</strong></p>\n\n<ul>\n<li>A 12-lead ECG and blood pressure measurement before starting</li>\n</ul>\n\n<p><strong>During the first 6 hours of treatment*:</strong></p>\n\n<ul>\n<li>Continuous ECG monitoring for 6 hours</li>\n\n<li>Blood pressure and heart rate measurement every hour</li>\n</ul>\n\n<p><strong>After 6 hours of treatment:</strong></p>\n\n<ul>\n<li>A further 12-lead ECG and blood pressure measurement</li>\n</ul>\n\n<p><strong>* If the patient&#8217;s heart rate at the end of the 6-hour period is at its lowest since fingolimod was first administered, the monitoring should be extended by at least 2 hours and until the heart rate increases.</strong></p>\n\n<p><strong>Additional criteria for extended monitoring:</strong></p>\n\n<p>In patients with evidence of clinically important cardiac effects during the first 6 hours of fingolimod treatment, monitoring should be extended, including at least overnight monitoring, until resolution. Recommended criteria for extending monitoring include:</p>\n\n<p>The occurrence at anytime during the monitoring period after first dose of:</p>\n\n<ul>\n<li>New-onset 3rd degree atrioventricular block</li>\n</ul>\n\n<p>The presence at the end of the monitoring period after first dose of:</p>\n\n<ul>\n<li>Heart rate less than 45 beats per minute</li>\n\n<li>QTc interval &#8805;500 ms.</li>\n\n<li>Persistent new-onset 2nd degree atrioventricular block, Mobitz Type I (Wenckebach) or higher degree atrioventricular block</li>\n</ul>\n\n<p><strong>If fingolimod therapy is discontinued for more than 2 weeks for any reason, the effects on heart rate and atrioventricular conduction may recur on its reintroduction and so the same monitoring precautions as for treatment initiation should apply.</strong></p>\n\n<p><strong>Reporting of suspected adverse drug reactions</strong></p>\n\n<ul>\n<li>All suspected adverse reactions to fingolimod should be reported to us promptly on a Yellow Card, available at <a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard</a></li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"http://http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdf\" target=\"_blank\">Statement from the European Medicines Agency</a></p>\n\n<p><a href=\"/home/groups/comms-ic/documents/websiteresources/con152562.pdf\" target=\"_blank\">Letter on fingolimod sent to healthcare professionals in April 2012</a></p>\n\n<p><a href=\"http://www.medicinescomplete.com/mc/bnf/current/4789.htm\" target=\"_blank\">BNF section 8.2.4 Other immunomodulating drugs</a></p>\n\n<p><em>Article citation: Drug Safety Update May 2012, vol 5 issue 10: A1</em></p>\n\n&#160;-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Fingolimod (Gilenya) is authorised to treat relapsing-remitting multiple sclerosis in patients whose disease has failed to respond to beta-interferon or is severe and getting worse rapidly. Fingolimod is a sphingosine -1 phosphate receptor ligand.</p>\n\n<p>We first highlighted changes to the monitoring advice for fingolimod in <a href=\"http://http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON143608\" target=\"_blank\">February 2012.</a></p>\n\n<p>We now provide updated advice to avoid use in high risk groups and extend monitoring in some patients. The latest advice follows further review of world-wide data including 15 cases of sudden or unexplained death with fingolimod. Most of the deaths and cardiovascular events had occurred in patients with either a history of cardiovascular problems, such as atrioventricular block or bradycardia, or those who were also taking other medicines. However the data reviewed were not conclusive as to whether Gilenya was the cause of the deaths.</p>\n\n<p>The maximum effect of fingolimod on decreasing the heart rate occurred within six hours after the first dose in most patients; this decrease in heart rate can be reversed if necessary by giving atropine or isoprenaline (see statement from the <a href=\"http://http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdf\" target=\"_blank\">European Medicines Agency</a>).</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Updated advice:</strong></p>\n\n<p><span style=\" text-decoration: underline;\"><strong>Fingolimod is now not recommended in the following high-risk patients:-</strong></span></p>\n\n<p>a) <strong>Those with the following medical conditions:</strong></p>\n\n<ul>\n<li>2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block</li>\n\n<li>Significant QT prolongation (QTc &gt;470 ms in women, or &gt;450 ms in men)</li>\n\n<li>History of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnea.<br>\n</li>\n</ul>\n\n<p>b) <strong>Those receiving the following antiarrhythmic or heart-rate-lowering drugs:</strong></p>\n\n<ul>\n<li>Class Ia antiarrhythmics (eg, quinidine, disopyramide) or class III antiarrhythmics (eg, amiodarone, sotalol)</li>\n\n<li>Beta blockers</li>\n\n<li>Heart rate-lowering calcium channel blockers (eg, verapamil, diltiazem or ivabradine)</li>\n\n<li>Other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic agents or pilocarpine).</li>\n</ul>\n\n<p>In such patients, treatment with Gilenya should be considered only if the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought prior to initiation of Gilenya treatment. This advice should include, if appropriate, the possibility to switch any concomitant medicine to treatments that are not antiarrhythmic and do not lower the heart rate. If treatment with Gilenya for these patients is considered, monitoring at least overnight following the first dose should be initiated.</p>\n\n<p><strong><span style=\" text-decoration: underline;\">Updated monitoring advice: For all patients receiving fingolimod, monitoring before, during and after the first dose should include:</span></strong></p>\n\n<p><strong>Pre-treatment:</strong></p>\n\n<ul>\n<li>A 12-lead ECG and blood pressure measurement before starting</li>\n</ul>\n\n<p><strong>During the first 6 hours of treatment*:</strong></p>\n\n<ul>\n<li>Continuous ECG monitoring for 6 hours</li>\n\n<li>Blood pressure and heart rate measurement every hour</li>\n</ul>\n\n<p><strong>After 6 hours of treatment:</strong></p>\n\n<ul>\n<li>A further 12-lead ECG and blood pressure measurement</li>\n</ul>\n\n<p><strong>* If the patient&#8217;s heart rate at the end of the 6-hour period is at its lowest since fingolimod was first administered, the monitoring should be extended by at least 2 hours and until the heart rate increases.</strong></p>\n\n<p><strong>Additional criteria for extended monitoring:</strong></p>\n\n<p>In patients with evidence of clinically important cardiac effects during the first 6 hours of fingolimod treatment, monitoring should be extended, including at least overnight monitoring, until resolution. Recommended criteria for extending monitoring include:</p>\n\n<p>The occurrence at anytime during the monitoring period after first dose of:</p>\n\n<ul>\n<li>New-onset 3rd degree atrioventricular block</li>\n</ul>\n\n<p>The presence at the end of the monitoring period after first dose of:</p>\n\n<ul>\n<li>Heart rate less than 45 beats per minute</li>\n\n<li>QTc interval &#8805;500 ms.</li>\n\n<li>Persistent new-onset 2nd degree atrioventricular block, Mobitz Type I (Wenckebach) or higher degree atrioventricular block</li>\n</ul>\n\n<p><strong>If fingolimod therapy is discontinued for more than 2 weeks for any reason, the effects on heart rate and atrioventricular conduction may recur on its reintroduction and so the same monitoring precautions as for treatment initiation should apply.</strong></p>\n\n<p><strong>Reporting of suspected adverse drug reactions</strong></p>\n\n<ul>\n<li>All suspected adverse reactions to fingolimod should be reported to us promptly on a Yellow Card, available at <a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard</a></li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"http://http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdf\" target=\"_blank\">Statement from the European Medicines Agency</a></p>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con152562.pdf\" target=\"_blank\">Letter on fingolimod sent to healthcare professionals in April 2012</a></p>\n\n<p><a href=\"http://www.medicinescomplete.com/mc/bnf/current/4789.htm\" target=\"_blank\">BNF section 8.2.4 Other immunomodulating drugs</a></p>\n\n<p><em>Article citation: Drug Safety Update May 2012, vol 5 issue 10: A1</em></p>\n\n&#160;\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-05-01", 
  "date_last_modified": "2012-05-22", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Letter on fingolimod sent to healthcare professionals in April 2012", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con152562.pdf", 
      "filename": "downloads/6f7c336d063eab22d6e3fa609b275ef55e7b87c9/con152562.pdf", 
      "original_filename": "con152562.pdf"
    }
  ], 
  "_item_id": 114, 
  "summary": "Fingolimod is known to cause transient bradycardias and heart block after the first dose. Fingolimod is now not recommended in patient groups at high risk of cardiovascular adverse events, such as those with significant QT prolongation or history of bradycardia, ischaemic heart disease, cardiac failure, cerebrovascular disease, uncontrolled hypertension, and those receiving antiarrhythmic or heart-rate lowering drugs.\n\nMonitoring advice after the first dose has been updated. All patients should be monitored before, during, and immediately after the first 6 hours of treatment. If the patient’s heart rate decreases to its lowest point at the end of the 6-hour treatment period, monitoring should be extended until heart rate increases. Monitoring should also be extended at least overnight if significant atrioventricular block, bradycardia, or QTc prolongation occurs (see below)", 
  "body": "Article date: May 2012\n\nFingolimod (Gilenya) is authorised to treat relapsing-remitting multiple sclerosis in patients whose disease has failed to respond to beta-interferon or is severe and getting worse rapidly. Fingolimod is a sphingosine -1 phosphate receptor ligand.\n\nWe first highlighted changes to the monitoring advice for fingolimod in [February 2012.](http://http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON143608)\n\nWe now provide updated advice to avoid use in high risk groups and extend monitoring in some patients. The latest advice follows further review of world-wide data including 15 cases of sudden or unexplained death with fingolimod. Most of the deaths and cardiovascular events had occurred in patients with either a history of cardiovascular problems, such as atrioventricular block or bradycardia, or those who were also taking other medicines. However the data reviewed were not conclusive as to whether Gilenya was the cause of the deaths.\n\nThe maximum effect of fingolimod on decreasing the heart rate occurred within six hours after the first dose in most patients; this decrease in heart rate can be reversed if necessary by giving atropine or isoprenaline (see statement from the [European Medicines Agency](http://http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdf)).\n\nUpdated advice:\n\nFingolimod is now not recommended in the following high-risk patients:-\n\na) Those with the following medical conditions:  \n  \n  * 2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block  \n  * Significant QT prolongation (QTc >470 ms in women, or >450 ms in men)  \n  * History of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnea.  \n  \n  \nb) Those receiving the following antiarrhythmic or heart-rate-lowering drugs:  \n  \n  * Class Ia antiarrhythmics (eg, quinidine, disopyramide) or class III antiarrhythmics (eg, amiodarone, sotalol)  \n  * Beta blockers  \n  * Heart rate-lowering calcium channel blockers (eg, verapamil, diltiazem or ivabradine)  \n  * Other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic agents or pilocarpine).  \n  \nIn such patients, treatment with Gilenya should be considered only if the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought prior to initiation of Gilenya treatment. This advice should include, if appropriate, the possibility to switch any concomitant medicine to treatments that are not antiarrhythmic and do not lower the heart rate. If treatment with Gilenya for these patients is considered, monitoring at least overnight following the first dose should be initiated.\n\nUpdated monitoring advice: For all patients receiving fingolimod, monitoring before, during and after the first dose should include:\n\nPre-treatment:  \n  \n  * A 12-lead ECG and blood pressure measurement before starting  \n  \nDuring the first 6 hours of treatment*:  \n  \n  * Continuous ECG monitoring for 6 hours  \n  * Blood pressure and heart rate measurement every hour  \n  \nAfter 6 hours of treatment:  \n  \n  * A further 12-lead ECG and blood pressure measurement  \n  \n* If the patient’s heart rate at the end of the 6-hour period is at its lowest since fingolimod was first administered, the monitoring should be extended by at least 2 hours and until the heart rate increases.\n\nAdditional criteria for extended monitoring:\n\nIn patients with evidence of clinically important cardiac effects during the first 6 hours of fingolimod treatment, monitoring should be extended, including at least overnight monitoring, until resolution. Recommended criteria for extending monitoring include:\n\nThe occurrence at anytime during the monitoring period after first dose of:  \n  \n  * New-onset 3rd degree atrioventricular block  \n  \nThe presence at the end of the monitoring period after first dose of:  \n  \n  * Heart rate less than 45 beats per minute  \n  * QTc interval ≥500 ms.  \n  * Persistent new-onset 2nd degree atrioventricular block, Mobitz Type I (Wenckebach) or higher degree atrioventricular block  \n  \nIf fingolimod therapy is discontinued for more than 2 weeks for any reason, the effects on heart rate and atrioventricular conduction may recur on its reintroduction and so the same monitoring precautions as for treatment initiation should apply.\n\nReporting of suspected adverse drug reactions  \n  \n  * All suspected adverse reactions to fingolimod should be reported to us promptly on a Yellow Card, available at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)  \n  \nFurther information:\n\n[Statement from the European Medicines Agency](http://http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdf)\n\n[ASSET_TAG](#ASSET0)\n\n[BNF section 8.2.4 Other immunomodulating drugs](http://www.medicinescomplete.com/mc/bnf/current/4789.htm)\n\nArticle citation: Drug Safety Update May 2012, vol 5 issue 10: A1\n\n \n"
}